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INTRODUCTION
In the 1930s, it was estimated that 1% to 2% of all pregnancies were complicated by maternal 
cardiac disease and that 6% of these women died  during pregnancy. The current estimated clinical 
prevalence of clinically  significant cardiac disease during pregnancy is similar (0.1% -1.4%)14,27; 
however the maternal mortality for these patients during pregnancy has decreased to 0.5% to 2.7%14,27. 
Nevertheless, cardiac disease contributes to 15% of maternal mortality. 
Although patients with significant cardiac disease were discouraged strongly from becoming 
pregnant in the past, the vast improvements in cardiac care and vast improvements in reproductive 
technology may result in more women who have cardiac diseases planning pregnancies. As pregnancy 
represents a unique heamodynamic state with profound implications for cardiac function, obstetricians 
and cardiologists must be prepared to provide optimal care to these patients.
                               
REVIEW OF LITERATURE
Rheumatic heart disease results from single or repeated attacks of rheumatic fever that produces 
rigidity and deformity of valve cusps ,fusion of the commissures, or shortening and fusion of the 
chordae tendinae. Stenosis or  insufficiency results, and the two often co exist. The mitral valve is 
affected  in 50-60% of cases; combined lesions of the aortic and mitral valves occur in  20%; pure 
aortic valve lesions are less common. Tricuspid valve involvement occurs in 10% of cases, but only 
in association with mitral or aortic valve disease and is thought to be more common when recurrent 
infection occur. The pulmonary valve is rarely affected. 
A history of  rheumatic fever is obtained only in 60% of patients with rheumatic valve disease. 
With advance in medical care more number of women in child bearing age are undergoing valve 
replacement procedures bringing with it problems related to anticoagulation and its impact on future 
pregnancies. These women have to be counseled on the maternal and fetal effects of these drugs on 
pregnancy.
HEAMODYNAMIC CHANGES IN PREGNANCY
Parameter modification Magnitude Peak Reference
O2 consumption 
(vo2)
Increased   +20%
  +40-60%
  Term Gemzell 1957
Pernoll 1975
O2 delivery Increased 700-
1400ml\min
  Term Hankins 1996
Blood volume
Plasma
RBC
Increased
Increased
+45-50%
+25-32%
 32 wk
 30-32 wks
Mclennon 1984
Letsky 1995
Total body water Increased
 
 +6-+8L   Term
Satchilk 1967
Lindhrime 1973
Resistance 
changes
Systemic
Pulmonary
Decreased
Decreased
-2%
-34%
16-24 wks
 34 wks
Kitabatak 1983
Clark 1989
Blood pressure
Systolic 
Diastolic
Both decreased  -9% 25 wks Wilson 1980
Cardiac output Increased +30-50% Term Van opel1996
Myocardial 
contractility 
Chronotropism 
(HR)
Ionotropism (SV) 
Both increased +20to30%
+11to32%
Term Wilson 1980 
Utero  placental 
circulation 
Increased +100% Term Metcalfe 1955
DIAGNOSIS
Many  of  the  physiological  adaptation  of  normal  pregnancy  alter  physical 
findings, making the diagnosis of the heart disease more difficult.
CLINICAL INDICATORS OF HEART DISEASE DURING PREGNANCY 35
SYMPTOMS 
Progressive dyspnea or orthopnea 
Nocturnal cough 
Hemoptysis 
Syncope 
Chest pain 
CLINICAL FINDINGS
Cyanosis 
Clubbing of fingers
Persistent neck vein distension 
Systolic murmur grade 3/6 or greater 
Diastolic murmur 
Cardiomegaly
Persistent arrhythmia 
Criteria for pulmonary hypertension. 
Information  regarding  rheumatic  fever  and  penicillin  prophylaxis  need  to  be 
elicited in history taking. It has been noted that only 60%1 with rheumatic heart disease 
give a history of previous rheumatic fever.
Cardiac  auscultation  remains  the  most  widely  used  method  for  screening  for 
valvular heart disease. In instances like valvular aortic stenosis, detection of a cardiac 
murmur gives a clue to the detection of a cardiac disease when asymptomatic, or may 
define the reason for cardiac symptoms. A diastolic murmur however, virtually always 
represents pathological conditions and requires further evaluation.
ECG  is  important  in  providing  negative  information  at  a  low  cost  like  the 
presence of ventricular hypertrophy, atrial enlargement and arrythmias. 
Non-invasive investigation like an echocardiography with color flow and spectral 
Doppler evaluation is a very important  tool  for  assessing the significance of cardiac 
murmurs and is also the best screening procedure though costly. Information regarding 
valve  morphology  and  function,  chamber  size,  wall  thickness,  ventricular  function, 
pulmonary and hepatic vein flow, and estimates of pulmonary arterial pressures can be 
readily obtained with the help of an echo 31.
NYHA (NEW YORK HEART ASSOCIATION) CLASSIFICATION 
CLASS 1 UNCOMPROMISED (no limitation of physical activity)       
These  women  do  not  have  symptoms  of  cardiac  insufficiency  or  experience 
anginal pain 
CLASS 2 (slight limitation of physical activity) 
These  women  are  comfortable  at  rest,  but  if  extra  ordinary  physical  activity 
(unaccustomed)  is  undertaken,  discomfort  results  in  the  form  of  excessive  fatigue, 
palpitation, dyspnea, or anginal pain.
CLASS 3(marked limitation of physical activity) 
These women are comfortable at rest, but less than ordinary activity (accustomed) 
cause excessive fatigue, palpitation, dyspnea, or anginal pain.
CLASS 4 severely compromised (inability to perfom any physical activity without 
discomfort) 
Symptoms of cardiac insufficiency or angina may develop even at rest, and if any 
physical activity is undertaken, discomfort is increased.
RISKS  FOR  MATERNAL MORTALITY CAUSED  BY VARIOUS  TYPES  OF 
HEART DISEASE (ACOG 1992)
GROUP 1-Minimal Risk (0-1%)
Atrial septal defect 
Ventricular septal defect 
Patent ductus arteriosus 
Pulmonic or tricuspid disease 
Fallot tetrology, corrected 
Bioprosthetic valve 
Mitral stenosis NYHA class 1 and 2 
GROUP 2- Moderate Risk (5-15%) 
2A: 
Mitral stenosis, NYHA class3 and 4                      
Aortic stenosis 
Aortic coarctation without valvular involvement 
Fallot tetralogy, uncorrected 
Previous myocardial infarction 
Marfans syndrome, normal aorta 
2B: 
Mitral stenosis with atrial fibrillation 
Artificial valve 
GROUP 3-Major Risk (25-50%) 
Pulmonary hypertension 
Aortic coarctation with valvular involvement 
Marfans syndrome with aortic involvement
VALVULAR HEART DISEASE ASSOCIATED WITH HIGH 
MATERNAL RISK DURING PREGNANCY. 
        1. Severe aortic stenosis (AS) with or without symptoms.
     2. Aortic regurgitation (AR) with NYHA class III-IV symptoms
     3.  Mitral stenosis (MS) with NYHA class II-IV symptoms.
     4.  Mitral regurgitation (MR) with NYHA class III-IV symptoms
     5. Aortic or mitral valve disease with severe pulmonary hypertension 
          (pulmonary pressure >75% systemic pressure)
     6. Aortic or mitral valve disease with severe left ventricular               
         dysfunction (ejection fraction<40%)          
     7. Mechanical prosthetic valve requiring anticoagulation
     8. AR in Marfans syndrome
VALVULAR HEART LESIONS ASSOCIATED WITH LOW
MATERNAL AND FETAL RISKS DURING PREGNANCY5
1.   Asymptomatic AS with low mean gradient (<50mm Hg) with  normal LV systolic 
function (ejection fraction>50%)
    2.   NYHA class I-II AR with normal LV systolic function.
    3.   NYHA class I-II MR with normal LV systolic function.
    4.  Mild to moderate MS (mean valve area >1.5cm2, gradient<5mm Hg) without 
severe pulmonary hypertension.
    5.   Mild to moderate pulmonic stenosis.
6. Mitral valve prolapse with no MR or with mild to moderate MR with normal 
systolic flow
PRECONCEPTION CONSIDERATIONS
Optimization of maternal status 
• Repair structural defects before pregnancy when indicated
• Adjust  medications  to  optimize  maternal  functional  capacity  and minimize  foetal 
effects
Discussion of foetal risks
• Counsel patients regarding risk to foetus due to the maternal cardiac condition or the 
medications taken.
ANTEPARTUM CONSIDERATIONS
• Regular antenatal visits
• Rigorously treat anemia and urinary tract infections.
• Anticoagulation in patients with mechanical heart valves and atrial arrythmias.
INTRAPARTUM CONSIDERATIONS
• Labour is the most dangerous period for many patients having cardiac disease; this is 
the period of the greatest increase in cardiac output.
• Vaginal delivery is preferred over caesarean section for most patients because of less 
blood loss,  fewer  postpartum infections,  and earlier  ambulation  with  less  risk  of 
thrombosis and pulmonary complications.
• An assisted second stage to shorten labor and to decrease dramatic fluid shifts that 
are associated with active pushing.
• Endocarditis prophylaxis in high risk patients.
• Treat postpartum hemorrhage aggressively to prevent hypovolemia.
ANESTHETIC CONSIDERATIONS
 Regional anesthesia is appropriate for most patients with heart disease. Benefits of good 
pain control include:
(a) avoidance  of  maternal  tachycardia  which  is  important  in  patients  with 
mitral  stenosis  in whom left  ventricular  filling is  impaired if  diastole  is 
shortened;
(b) decreased cardiac work
(c) the ability to perform an assisted vaginal delivery.
Patients with stenotic valve lesions do not tolerate sudden decrease in systemic 
vascular  resistance.  Epidural  anesthesia  must  be  administered  slowly  or  intrathecal 
analgesics  may  be  used.  For  caesarean  delivery,  these  patients  may  require  general 
anesthesia. Spinal anesthesia is contraindicated because of associated hypotension that is 
deleterious on the compromised heart.
POSTPARTUM CONSIDERATION                                                      
Patients  remain  at  high  risk  for  thromboembolism  during  postpartum  period. 
Prophylactic anticoagulation should be given for 6 weeks postpartum for patients with 
mechanical heart valves and atrial fibrillation.
CONTRACEPTION9
Contraceptive advice is needed from adolescence onwards and the implication of 
an unplanned pregnancy in an unprepared cardiac patient should be discussed with all 
young adults with heart disease. Barrier method of contraception is unreliable and the 
combined contraceptive pill is contraindicated in all conditions where thrombosis and 
paradoxical embolism is a risk. Progesterone only preparation have a better side effect 
profile  and  long  acting,  slow  release  preparations,  such  as  implanon  and  mirena 
intrauterine system, have improved efficacy compared to oral preparations. Preinsertion 
screening for genito-urinary infection is recommended as is endocarditis prophylaxis to 
cover the insertion procedure. Sterilisation may be considered according to the wishes of 
the couple. Laproscopic clip sterilization is contraindicated  because carbon- di- oxide 
pnemoperitoneum  and  trendelenberg  position  is  not  tolerated  by  these  patients. 
However,  it  is  recognized  that  women  with  serious  defects  have  a  shortened  life 
expectancy and the partner may wish to preserve his fertility to have a family in the 
future.
ENDOCARDITIS PROPHYLAXIS
Endocarditis is believed to occur from bacterial seeding of damaged heart valves 
and bacteremia occurs with only 1-5%23,30 of deliveries. Hence, the  ACC\AHA does not 
routinely  recommend  antibiotic  prophylaxis  for  patients  with  valvular  heart  disease 
undergoing vaginal or caesarean delivery. Clinical infections, such as chorioamnionitis, 
may  be  associated  with  bacteremia,  and    therefore,  endocarditis  prophylaxis  is 
warranted. In addition, the ACC\AHA allow for “optional” endocarditis prophylaxis for 
patients having a history of endocarditis or high risk cardiac lesions such as prosthetic 
valves.
          Despite  these  recommendations  many  obstetricians  routinely  administer 
antibiotics during labor or at the time of caesarean delivery.
          Surgue et al32 collected serial blood cultures from 83 patients following vaginal 
deliveries. They found a 3.6% incidence of bacteremia but noted a possible increased 
risk with manual removal of placenta. A concurrent series of 2165 patients who had 
cardiac disease revealed a 0.09% of endocarditis following pregnancy, but these patients 
had  manual  removal  of  placenta.  This  is  a  complication  of  delivery  that  cannot  be 
predicted.  Therefore  many  obstetricians  liberalize  the  administration  of  prophylactic 
antibiotics at the time of delivery. This must be weighed against the risks of promoting 
bacterial resistance
ENDOCARDITIS PROPHYLAXIS REGIMEN FOR
GENITOURINARY/GASTROINTESTINAL(EXCLUDING 
ESOPHAGEAL)PROCEDURES5
SITUATION AGENTS REGIMEN
High risk patient Ampicillin 
+gentamicin
Ampicillin  2gm  IM/IV  plus  gentamicin 
1.5mg/kg  (not  to  exceed120mg)  within  30 
minutes  of  starting  the  procedure.Six  hours 
later,  ampicillin  1.0gm  IM/IV  or  ampicillin 
1.0gm orally.
High risk patient 
allergic to 
ampicillin
Vancomycin 
+gentamicin
Vancomycin  1.0gm  IV  over  1-2  hours  plus 
gentamicin  1.5mg/kg  (not  to  exceed 
120mg).Complete  infusion  within  30  mts  of 
starting the procedure
Moderate risk 
patient 
Amoxycillin 
or ampicillin
Amoxicillin 2.0gm orally 1hr before procedure 
or  ampicillin  2.0gmIM/IV  within  30mts  of 
starting the procedure.
Moderate risk 
patient allergic to 
ampicillin
Vancomycin Vancomycin 1.0gm IV over 1-2hours.Complete 
infusion within 30mts of starting the procedure. 
AMERICAN HEART ASSOCIATION RECOMMENDATION FOR ANTIBIOTIC 
PROPHYLAXIS TO PREVENT BACTERIAL ENDOCARDITIS (2003)23
CARDIAC LESION
PROPHYLAXIS FOR 
UNCOMPLICATED 
DELIVERY
PROPHYLAXIS FOR 
SUSPECTED 
BACTEREMIA
HIGH RISK CATEGORY 
Prosthetic cardiac valves
Optional Recommended
Previous bacterial 
endocarditis
Optional Recommended
MODERATE RISK 
Acquired valvular 
dysfunction(most 
commonly R H D)
Not recommended Recommended
Mitral valve prolapse with 
valvular regurgitation or 
thickened leaflet or both 
Not recommended Recommended
LOW RISK 
Previous rheumatic fever 
without valvular 
dysfunction
Not recommended Not recommended
MITRAL STENOSIS (MS)
Mitral  stenosis  occurs  most  commonly  as  a  consequence  of  rheumatic  heart 
disease.  Complications  include  pulmonary  edema,  right  ventricular  failure,  atrial 
arrythmias and embolisation. Pregnancy is detrimental to cardiac function in the setting 
of mitral stenosis for several reasons. Expanded  blood volume can increase the risk of 
pulmonary congestion and  oedema. The physiologic tachycardia of pregnancy decreases 
left  ventricular  filling  time  leading  to  elevated  left  atrial  pressures  and  pulmonary 
edema,  decreased forward flow  causes hypotension ,fatigue and syncope.
Normal mitral valve area5 is 4-5 cm2
SEVERITY5
MITRAL VALVE AREA SEVERITY
                      >1.5cm2                  Mild
                  1.1-1.5 cm2                  moderate  
                   <=1 cm2                  Severe
In a prospective study of 80 pregnancies in 74 women who had mitral stenosis, 
the rate of maternal cardiac complications was 35% and the rate of adverse fetal and 
neonatal outcomes was 30%. There were no cases of stroke, cardiac arrest or death in 
this series, nor was there a need for invasive interventions. The incidence of maternal 
and fetal complications was associated significantly with the severity of MS based on 
valve area. The pre-pregnancy NYHA classification did not correlate with maternal and 
fetal outcomes29; however all women in this series had class1 or II disease. With class III 
and class IV previous series reported maternal mortality rates of 5% to 7% and perinatal 
mortality rates of 12% to 31%26,33.
Treatment 
Medical
Treatment of mitral stenosis in patients who have a history of rheumatic heart 
disease  includes,  daily  prophylactic  penicillin,  gentle  diuresis  to  prevent  pulmonary 
edema without decreasing placental perfusion, and beta blockers as needed to prevent 
tachycardia. New onset atrial fibrillation can be treated  with cardioversion; digoxin or 
beta  blockers  may  be  used  for  rate  control  in  atrial  fibrillation.  Patients  with  atrial 
fibrillation should be anticoagulated to prevent systemic embolisation.
Surgical
The surgical treatment of mitral stenosis during pregnancy include closed mitral 
commisurotomy balloon mitral valvuloplasty(BMV) .Valve replacement is usually best 
avoided during pregnancy due to high maternal and fetal morbidity and mortality.
Indications for CMC AND BMV:
• being failure of medical therapy with intractable  medical symptoms
•  history of pulmonary edema with risk of recurrence in pregnancy 
•  profuse hemoptysis.
• Asymptomatic  patients  with  pulmonary  hypertension(PASP>50mm 
Hg).
Contraindications for CMC and BMV:
• calcified valve 
• the presence of moderate to severe MR.
Ideally, this should be done before conception in symptomatic women who have severe 
MS.  For  women  with  severe  MS  with  clinical  deterioration  during  pregnancy,  the 
procedure can be done safely done during pregnancy. It was shown to carry less fetal 
risk than open mitral commisurotomy.
Labour Management    
During  labour,  adequate  pain  relief  using  intrathecal  narcotics  is  important  to 
prevent tachycardia and its consequences. Epidural anesthesia can cause hypotension in 
an already compromised MS patient. 
MITRAL REGURGITATION (MR)
Mitral regurgitation (MR) in pregnant women is most commonly due to  mitral 
valve  prolapse,  though  rheumatic  heart  disease  remains  an  important   cause  in 
developing countries.  The heamodynamic changes  of  pregnancy are   beneficial  to  a 
patient who has MR , because a state of increased volume and  decreased systemic 
vascular resistance promotes forward flow across the  regurgitant valve. Pregnancy is 
usually well tolerated.
           VALVE JET AREA               SEVERITY
                   <=4 cm2                       Mild
                   5-8  cm2                       Moderate
                   >=9 cm2                       Severe
The small number of patients who develop pulmonary congestion can be treated 
with  diuretics.  Vasodilators  such  as  hydralazine,  are  beneficial  in   women  having 
associated systemic hypertension. Severe MR can lead to marked left atrial dilatation 
and consequent atrial fibrillation. Epidural anesthesia can be safely used with adequate 
intravenous(IV) hydration.
AORTIC STENOSIS (AS)
The most common cause of AS in younger women is a congenital bicuspid aortic 
valve. Rheumatic heart disease is a less common cause in the western world though it 
may be seen in less developed countries.
                        Severity      Valve area   /Peak gradient
                          Mild           >1.5cm2   /<36mm Hg
                          Moderate          1-1.5cm2 /36-63mm Hg
                          Severe           <1cm2    />=64mm Hg
Women who have severe stenosis or symptoms are advised to undergo surgical 
repair before attempting pregnancy5. Patients having severe AS have difficulty achieving 
an increased cardiac output that is required by pregnancy. Their stroke volume is fixed 
by  the  obstructed  valve.  Heart  rate  is  the  key  determinant  of  cardiac  output,  both 
tachycardia and bradycardia being detrimental.
In a Toronto study29 from 1986-2000 of 49 pregnancies in women who had AS, all 
belonged to NYHA class I and II at the time of enrollment. Pregnancy was generally 
well  tolerated.  Ten  percent  of  patients  (3/29)  with  severe  disease  had  early  cardiac 
complications (pulmonary edema or atrial arrythmias) during pregnancy; the remaining 
20 patients with mild to moderate disease did not have  pregnancy complications. 
Twelve percent  of  pregnancies were complicated by preterm labor,  respiratory 
distress syndrome, or intrauterine growth restriction (IUGR); this rate is similar to that 
seen  in  the  general  population.  In  1000  patients  studied  in  Brazil  2from 1989-1999 
68.5% of patients had no complications. 
The subset of patients having moderate to severe AS had morbidity, including 
congestive cardiac failure, angina, two patients needed valve replacement, and there was 
one sudden death.
Mild to moderate AS in pregnancy is managed conservatively. For women who 
have severe symptomatic disease in pregnancy, balloon valvuloplasty has been reported 
without complications. This procedure is contraindicated in the presence of significant 
aortic regurgitation (AR). Open valve replacement is also an option for patients who 
have decompensation during pregnancy, but it is associated with a foetal mortality of 
30%9.
 During labor,  epidural  anesthesia  may be used cautiously,  with generous  fluid 
hydration to prevent hypotension and reflex tachycardia. In these patients postpartum 
hemorrhage  should  be  treated  aggressively,  as  the  decrease  in  preload  can  be 
catastrophic.
AORTIC REGURGITATION (AR)
In acute AR, as there is no time to accommodate increase in regurgitant volume 
by the normal sized LV, the patient presents with pulmonary edema and cardiogenic 
shock.
 In chronic AR, compensatory mechanisms counteract the left ventricular volume 
overload. Hence majority of the patients remain asymptomatic. Vasodilator therapy has 
the potential to reduce heamodynamic burden in such patients.
MECHANICAL HEART VALVES
Pregnant women who have mechanical heart valves present one of the greatest 
challenges to obstetricians and cardiologists. These women have a maternal mortality 
rate  of  1-4%8,13 secondary  to  valve  thrombosis,  despite  anticoagulation.  Therefore, 
women with valvular heart disease desiring  future child bearing should be considered 
for valve replacement with a biological valve, if possible34.
Optimal anticoagulation for these women during pregnancy has become a subject 
of great controversy. Out side of pregnancy, warfarin is the preferred anticoagulant for 
patients who have mechanical heart valves. The addition of aspirin has been shown to 
provide added protection. The goal INR for mechanical valves patient is 2.5to3.55.
   Generally  warfarin  is  considered  to  be  contraindicated  during  pregnancy  for 
several  reasons.  It  may  lead  to  warfarin  embryopathy  consisting  of  nasal  and  limb 
hypoplasia, epiphysial stippling and CNS abnormalities in 5to10% of foetuses but this 
risk can be eliminated if heparin is substituted for warfarin from 6to12 weeks gestation8. 
It can also cause intracranial hemorrhage in the fetus during vaginal delivery.
When  unfractionated  heparin  has  been  substituted  for  warfarin  throughout 
pregnancy, thromboembolism rates of 33% have been reported; this is equivalent to the 
rates of thromboembolism with no anticoagulation. When heparin was substituted for 
warfarin from 6to12 weeks of gestation only, the rate of thromboembolism was 9.2% 
compared with 3.9% in patient who received warfarin throughout pregnancy8. High rates 
of thrombosis with heparin are suspected to be secondary to inadequate dosages.
ACC\AHA recommendations for anticoagulation during pregnancy in women with 
mechanical prosthetic valves5
1 through 35 weeks
• The decision on the choice of anticoagulant must be made after full discussion 
with the patient on the side effects of medications.
• High  risk  women  (H\O  thrombembolism,  older  valve  prosthesis)  on  IV 
unfractionated heparin, dosage given should maintain aPTT at 2-3 times control.
• High risk women on warfarin , INR should be maintained between 2.0-3.0 and 
low dose aspirin should be given.
• Low risk women may be managed with adjusted SC heparin (17,500-20,000 IU 
BD) maintaining aPTT 2-3 times control.
After the 36th week
• Warfarin is stopped by 36 weeks and heparin substituted.
• If labor begins during treatment with warfarin, a cesarean should be  performed 
due to risk of intracranial hemorrhage to foetus.
• In the absence of significant bleeding, heparin can be started 4-6 hrs after delivery 
and warfarin can be given orally.
PROGNOSIS-IN-RHEUMATIC HEART DISEASE 
In the long run, pregnancy does not adversely affect the survival of a woman with 
rheumatic heart disease, once she has survived the pregnancy itself.
The nulliparous patient with heart disease fares no better in life than the parous 
woman,  and  the  death  rate,  age  for  age,  shows no  difference  between  two groups. 
Statistically,  the  death  rate  does  not  appear  to  be  influenced  by  the  number  of 
pregnancies.
 Patients with rheumatic heart disease have good prognosis, if they receive good 
antenatal supervision. The immediate death rate is around 1-2%, and of the survivors, 
more than half have no alteration in cardiac grading. There is a tendency for patient to 
drop one class during the course of her pregnancy.
A history of  cardiac failure  prior  to  pregnancy, and atrial  fibrillation are  poor 
prognostic signs. mitral stenosis who may be asymptomatic at the on -set of pregnancy 
but may go in to failure in late pregnancy. The prognosis become clear by 28 to 32 
weeks of pregnancy when the heart is shouldering its greatest load .If the patient is able 
to cope well at this time, the outlook of labour is good
EFFECTS  OF  CARDIOVASCULAR  DRUGS  TAKEN  DURING 
PREGNANCY 6,27,24
SUMMARY  OF  MATERNAL  MORTALITY  WITH  SELECTED  CARDIAC 
CONDITION 
CONDITION MATERNAL MORTALITY
Mitral stenosis 
    All mitral stenosis 2,29
    NYHA class III\IV 26,33
0-1.6%
5-7%
Aortic stenosis 
     All aortic stenosis 2,29 0-2%
Mechanical heart valve 8,13 1-4%
                                                 
                                   
AIMS OF THE STUDY
1. To  study  the  maternal  and  fetal  outcomes  in  pregnancies  complicated  by 
rheumatic heart disease in our institution over a period of one year.
    2.  To analyse possible prognostic factors that would enable us to formulate necessary 
guidelines for safe motherhood.
    3.  To analyse outcomes in surgically corrected heart disease.
MATERIALS AND METHODS
TYPE OF STUDY
Prospective  study.
MATERIALS
This study was conducted in The Institute of Obstetrics and Gynecology, Egmore, 
Chennai. One hundred and twenty nine (129) women with rheumatic heart disease were 
registered in this study from January 2006 to December 2006.
INCLUSION CRITERIA
All patients with Rheumatic heart disease (MS, MR, AR, AS:  as diagnosed from 
history, clinical examination and echocardiography) who were
• On long term treatment
• Newly diagnosed 
• Surgically operated on
•  And in need of medical termination and sterilization were included for the study.
EXCLUSION CRITERIA
Patients with
• Mitral valve prolapse with mitral regurgitation
• Isolated aortic stenosis
• Congenital heart disease
METHOD
All  patients  having  RHD,  outpatients,  inpatients  and  those  admitted  via  our 
emergency  department  were  meticulously  followed  up  antenatally  as  well  as  from 
admission till discharge. The clinical course during pregnancy and the maternal, foetal 
outcomes were studied.
PHYSICAL EXAMINATION
Height, weight, anemia, cyanosis, pedal edema, elevated jugular venous pressure, 
peripheral pulses, blood pressure, respiratory rate, cardiovascular system examination 
for systolic and diastolic murmurs, loud P2, respiratory  system examination for basal 
rales and wheeze and abdominal examination for organomegaly were done.
OBSTETRIC EXAMINATION
Uterine fundal height, abdominal girth and fetal heart were recorded.
LABORATORY INVESTIGATIONS
• Haemoglobin, haematocrit , total count, differential count.
• Urine for microscopic examination and deposits.
• Urine culture and sensitivity.
• ECG, ECHO
ROUTINE MANAGEMENT
Patients were routinely examined every antenatal visit  for signs of anemia and 
congestive  cardiac  failure.  They  were  usually  admitted  at  28-32  weeks  of  gestation 
unless they presented with symptoms of cardiac failure earlier in pregnancy. Frequency 
of the antenatal visits depended on the functional cardiac status. 
          Our patients were already under the supervision of cardiologists. Patients with 
severe disease were on the following drugs through out pregnancy:
Tab. Digoxin 0.25 mg 1-0-0 for five days a week.
Tab.furosemide 40 mg 1-0-0 twice a week
Tab.penicillin 250 mg 1-0-0 twice a day
Syrup Kcl 2 tsp twice daily
                They were advised to have adequate bed rest and take high calorie diet. 
Anemia was corrected by oral iron supplementation and urinary tract infection treated 
with appropriate antibiotics.
Patients in cardiac failure were treated with bed rest,  nasal  oxygen, parenteral 
diuretic , digoxin and vasodilators in the intensive care unit.
LABOUR MANAGEMENT
The  rule  was  to  wait  for  spontaneous  onset  of  labor.  Patients  were  put  in  a 
propped up position, an intravenous line was started, and nasal oxygen given. Epidural 
analgesia  was  routinely  given  to  all  our  patients  excepting  those  on  anticoagulants. 
Pulse, BP and foetal heart rate were carefully monitored and endocarditis prophylaxis 
was given to all patients at the onset of labour by ampicillin regimen.
             Outlet forceps was applied to shorten second stage of labour in many cases.  
Episiotomies  and  perineal  lacerations  were  meticulously  sutured.  LSCS  was  done 
strictly for obstetric indications alone. Monitoring in the ICU was done till 48 hours 
postpartum.  Babies  were  given  to  the  mothers  immediately,  unless  the  mother  was 
seriously ill. 
           Advice on contraception and spacing of  pregnancy was given.  Puerperal  
sterilization was done 6 weeks after delivery if desired. Patients were discharged 10-14 
days after delivery.
TABLE  I
INCIDENCE OF HEART DISEASE
TOTAL NO OF 
DELIVERIES
HEART DISEASE
TOTAL
INCIDENCE
18700 180 0.96%
TABLE II
INCIDENCE OF RHEUMATIC HEART DISEASE
HEART 
DISEASE PATIENTS WITH  RHD PERCENTAGE
180 129 71.6%
TABLE III
RHEUMATIC FEVER AND RHD
PATIENTS
WITH RHD
H\O RHEUMATIC 
FEVER
PERCENTAGE
129 84 65.1%
                              
TABLE  IV
OPERATED VS NON OPERATED RHD
RHEUMATIC 
HEART DISEASE
N0 OF PATIENTS PERCENTAGE
OPERATED 45 34.9%
NOT OPERATED 84 65.1%
TOTAL 129 100%
TABLE V
TYPE OF SURGERY FOR MITRAL VALVE LESIONS
RHEUMATIC HEART 
DISEASE
OPERATED PERCENTAGE
CLOSED MITRAL 
COMMISUROTOMY
36 80%
BALLOON MITRAL 
VALVULOPLASTY 
2 4.5%
MITRAL VALVE 
REPLACEMENT
6 13.5%
OPEN MITRAL 
VALVOTOMY 
1 2%
TOTAL 45 100%
TABLE  VI
TYPE OF LESION
TYPE OF LESION NUMBER PERCENTAGE
MITRAL  STENOSIS 60 46.5%
MITRAL 
REGURGITATION
27 20.9%
COMBINED 
MITRAL  VALVE 
LESIONS
21 16.3%
MULTIVALVULAR 
LESIONS
21 16.3%
TOTAL 129 100%
There were no lesions of isolated aortic regurgitation.                                 
TABLE VII
SOCIO-ECONOMIC STATUS
SOCIO ECONOMIC 
STATUS
NUMBER PERCENTAGE
CLASS I 0 0%
CLASS II 2 1.6%
CLASS III 10 7.6%
CLASS IV 41 31.6%
CLASS V 76 59.2%
TOTAL 129 100%
  
90.8% of patients belonged to class IV-V socioeconomic class.
TABLE VIII
AGE DISTRIBUTION
AGE NUMBER PERCENTAG
E
< =20 YRS           4         3.1%
21-24 YRS         76       58.9%
25-28  YRS         36       27.7%
>= 30 YRS         13       10.3%
   TOTAL       129       100%
               86.6% of patients were between 21-28 years. 
               The youngest was aged 18 years and the oldest
               35 years.
                                                   
TABLE IX
SEVERITY OF RHEUMATIC HEART DISEASE
SEVERITY(ECHO) NUMBER PERCENTAGE
MILD 6 4.7%
MODERATE 61 47.3%
SEVERE 62 48%
TOTAL
129 100%
95.3% of patients had moderate to severe disease.
TABLE X
NYHA FUNCTIONAL CLASS
           NYHA 
CLASSIFICATION
NUMBER PERCENTAGE
I                  4                 3.1%
II              101               78.3%
III               18                 14%
IV                6                 4.6%
TOTAL              129                100%
        
                          
TABLE XI
PREGNANCY OUTCOME
PREGNANCY
OUTCOME
NUMBER OF
PATIENTS
PERCENTAGE
 LABOUR 
NATURALIS
75 58.1%
OUTLET 
FORCEPS
24 18.6%
LSCS
PRIMARY
REPEAT
8
12
6.2%
9.3%
SPONTANEOUS 
ABORTIONS
2 1.6%
MTP 8 6.2%
TOTAL 129 100%
 
65.9% of patients had vaginal deliveries of which 15.5% were forceps deliveries; 
24.1% of patients had LSCS.
TABLE XII
BIRTH WEIGHT IN OPERATED VS NON OPERATED RHD
38.1% of babies were below 2.5 kg.
   
TABLE  XIII
LOW BIRTH WEIGHT IN OPERATED VS 
NOT OPERATED RHD
OPERATED NOT OPERATED
NO: OF BIRTHS 41 76
BIRTH WT<2.5 KG 8 38
PERCENTAGE 19.5 50
                                          
                                                  Chi2= 4.79
                                                  P <0.05
There were  50% of  babies  weighing less  than 2.5  kg  in the not  operated 
group as compared to 19.5% in the operated group and the association was found 
to be statistically significant.
 
TABLE  XIV
MATERNAL COMPLICATION IN RHD
OPERATED VS NON OPERATED
COMPLICATIONS
OPERATED NOT OPERATED
NO % NO %
PRETERM
2 1.6 20 15.5
PIH
1 0.8 4 3.1
CCF
6 4.7 18 13.9
ARRYTHMIA
0 0 1 0.8
EMBOLISM
0 0 1 0.8
FEVER
1 0.8 5 3.9
ANEMIA
5 3.9 13 10.1
TABLE XV
PRETERM BIRTHS IN OPERATED VS NON OPERATED RHD
OPERATED NOT OPERATED
NO: OF BIRTHS 41 76
PRETERMS 2 20
PERCENTAGE 4.8 26.3
                                                
                                                     Chi2= 5.82
                                                     P<0.05
The  incidence  of  preterm  births  was  26.3%  in  the  not  operated  group 
compared to  4.8% in  the  operated  group and the  association  was  found to  be 
statistically significant.
TABLE XVI
CCF IN OPERATED VS NON OPERATED RHD
      OPERATED  NOT OPERATED
 NO OF PATIENTS            45               84
           CCF             6                18
PERCENTAGE           13.3               21.4
                                                Chi2=0.76
                                                   P=0.68
                                                  
The incidence of CCF in the non operated group was 21.4% compared to 
13.3% in the not operated group which was not statistically significant.
TABLE XVII
                         PERINATAL COMPLICATION IN RHD
                          OPERATED VS NON- OPERATED      
    
COMPLICATIONS
    OPERATED NOT 
OPERATED
    NO        %     NO         %
              IUD         0        0       1          0.8
     STILL BIRTH         1       0.8       1          0.8
           SEPSIS         0        0       4          3.1
HYPERBILIRUBINEMI
A
        0        0       1          0.8
     BIRTH ASPHYXIA         1        0.8       4          3.1
             RDS         0         0       8          6.2
TABLE XVIII
PERINATAL MORTALITY IN   RHD
OPERATED VS  NOT OPERATED
  OPERATED   NOT OPERATED
NO: OF BIRTHS 41 76
PERINATAL  DEATH 1 9
PERCENTAGE 2.4 11.8
                                         Chi2 =5.82
                                          P<0.05
Perinatal mortality was 11.8% in the not operated group compared to 2.8% 
in the operated group which was statistically significant.
TABLE XIX
MATERNAL MORTALITY IN RHD
OPERATED VS NON OPERATED
                                              
OPERATED NOT OPERATED
NO: OF PATIENTS 45 84
NO: OF MATERNAL 
DEATHS
2 2
PERCENTAGE 4.4 2.3
There  were  2.3%  maternal  deaths  in  the  not  operated  group  and  4.4% 
maternal deaths in operated group.
                            
TABLE XX
CONTRACEPTION
FORM OF 
CONTRACEPTION
NO OF 
PATIENTS
PERCENTAGE
(%)
MTP WITH 
STERILIZATION
              8            6.2
LSCS WITH 
STERILIZATION
              12            9.3
PUERPERAL 
STERILIZATION
              7            5.4
COPPER-T                 4            3.1
BARRIER METHODS               15           11.6
VASECTOMY                 6            4.6
DISCUSSION
A study by Shawney et al26 on maternal and perinatal outcome in rheumatic heart 
disease in 486 pregnant patients with rheumatic heart disease concluded that RHD in 
pregnancy is associated with significant maternal and   perinatal morbidity in NYHA 
class III-IV patients.
Another study by Batla N et al3 on cardiac disease in pregnancy  in 207 patients 
concluded that rheumatic heart disease was the predominant type. Patients in NYHA 
class I/II  had a  better  maternal  and fetal  outcome than those in  NYHA class III/IV. 
Surgical correction of the cardiac lesion prior to pregnancy was associated with better 
pregnancy outcome. Pregnant women with prosthetic valves tolerated pregnancy well.
However, Malhotra M et al20  in their study on mitral valve surgery and maternal 
and fetal outcome in valvular heart disease in 308 patients concluded that mitral valve 
surgery before or  during pregnancy did not  significantly improve maternal  and fetal 
outcomes but  decreased adverse  events  such as  congestive  heart  failure  and cardiac 
arrhythmias. It should be therefore performed only in selected cases. 
A study by Butta SZ et al4 on pregnancy following cardiac surgery in 113 patients 
concluded that with appropriate care, the outcome of pregnancy in women who have had 
cardiac surgery is favorable, if their functional class is good.
A study by Lesnaik-Sobelga19 on clinical  and echocardiographic assessment of 
pregnant women with valvular heart diseases and maternal and fetal outcome concluded 
that pregnant women with critical mitral valve stenosis form a high-risk group of life-
threatening complications. In women with severe aortic stenosis, pregnancy could lead 
to sudden clinical status deterioration. Cardiac complications can be expected in patients 
with left  ventricular  enlargement  and its depressed function.  Key factors influencing 
successful  course  of  pregnancy  and  labour  in  patients  with  prosthetic  valves  were 
adequate  left  ventricular  function,  properly  functioning  valves,  and  effective 
anticoagulation.
Another study by Routray et al25 on balloon mitral valvuloplasty during pregnancy 
concluded that BMV is feasible, safe and effective. Maternal and fetal outcomes are 
excellent. Growth and milestone of development are not affected.
INCIDENCE 
This study was conducted in the Institute of Obstetrics and Gynecology, Egmore, 
Chennai during the year 2006-2007. The incidence of heart disease was found to be 
0.96%. This is comparable with other similar studies. 
                                                                        
Mudaliar and Menon 21 , 2005                     0.97%
Williams35, 2005                         1%
Present study 2006                    0.96%
About  129  women  with  rheumatic  heart  disease  were  included  in  this  study. 
Rheumatic heart disease constituted for 71.6% of heart disease in pregnancy. A study by 
Batla N et al3 in 2003 showed 88% incidence of RHD.
Batla N 32003                     88%
Present study 2006                   71.6%
  
RHEUMATIC FEVER AND RHD
In our study 65.1% of patients with RHD gave a history of prior rheumatic fever. 
This is comparable to 60% incidence quoted in CMDT 2007.
                CMDT 2007 1                        60%  
                Present study 2006                     65.1%
SOCIOECONOMIC STATUS
Most of these patients belong to socioeconomic status class IV-V (90.8%). This is 
comparable to data reported by Nafeesa Beebi et al (92%).
Nafeesa Beebi et al  1985                      92%
Present study 2006                   90.8%
TYPE OF LESION
Mitral stenosis has been found to be the dominant lesion in RHD.  Sawhney et 
al26showed that mitral stenosis was the most predominant lesion (89.2%) in 486 patients. 
Batla et al3 in 2003 had a 34.2% incidence of mitral stenosis in pregnancy. In our study 
involving 129 patients, 89(69%) had single valve involvement and mitral stenosis was 
the predominant lesion(48.1%).
STUDY DOMINANT MITRAL STENOSIS
Shawney et al 162003                               89.2%
Batla et al 4 2003                               34.2%
Present study 2006                               46.5%
SEVERITY AND FUNCTIONAL CLASS
REFERENCE NHYA  I AND II (%)
NYHA III AND IV 
(%)
Shawney et al 26 2003 77.4 22.6
Batla et al 3 2003 84.5 15.5
 Present study 81.4 18.6
From the above references it is clear that most patients belonged to NHYA I and 
II. However in our study sixty two (42%) of patients had severe valvular anatomical 
disease,  but  only  twenty  four  (18.6%)  belonged  to  NYHA class  III  and  IV.  Hence 
anatomical severity did not correlate with functional class.
MATERNAL COMPLICATIONS
            Batla et al 3 2003                       29.9%
            Present study 2006                       28.7%
The incidence of maternal complications was comparable between both studies. 
However there was no significant association (P=0.68) between the incidence of CCF in 
the operated and the not operated group in our study. 
PRETERM
Shawney et al 26 2003 12%
Present study 2006 18.8%
 
The incidence of preterm labour was comparable in both studies. However in our 
study we found a significant association (P<0.05) in incidence of preterm babies in the 
not- operated (26.3%) verses operated group (4.8%).
FETAL COMPLICATIONS
Batla et al 32003                          20.28%
Present study  2006                           20.5%
The incidence of fetal complications is comparable in both studies. We found a 
significant  association  (P<0.05)  in  the  incidence  of  low  birth  weight  babies  in  the 
operated (50%) versus not-operated (19.5%)  group in our study.
PERINATAL MORTALITY
Deepak Lahiri et al 111995                             5.4%
               Present study 2006                             8.5%
              Perinatal mortality is comparable in the above studies. There was a significant  
association (P<0.05%) between the operated (11.8%) verses not-operated (2.4%) group 
in our study.
MATERNAL MORTALITY
        Shawney  et al  26 2003                            2.05%
        Silversides CK et al 29 2003                   5-7%
        Present study 2006                              3.1%
The  maternal  mortality  is  comparable  in  both  studies.  There  were  totally  4 
maternal deaths: two in the operated group (4.4%) and two in the not-operated group 
(2.3%). All four patients died due to acute pulmonary edema secondary to CCF with 
severe mitral stenosis, two of whom were detected during incident pregnancy. 
CONTRACEPTION
Only 40.2% of  patients  opted  for  contraception  inspite  of  understanding risks 
associated with cardiac condition. All patients with valvular heart disease should use 
contraception in between pregnancies.
It is disturbing that 6.2% of patients underwent MTP with sterilization. All  of these patients were 
multigravidas. We recommend that these patients be encouraged to undergo interval sterilization 
after the second child.
PREGNANCY AFTER CARDIAC SURGERY
Butta et al 4 2003 Present study 2006
No of patients                113                 45
Patients with prosthesis                45%              13.5%
     CCF                16%                4.7%
Arrythmia                  4%                   0%
        PPH               3.5%                   0%
         PIH                  2%                 0.8%
Thromboembolism               0.6%                    0%
Maternal mortality                  0%                  4.4%
Abortion              10.6%                     0%
Still birth                   2%                  0.8%
Preterm                6.7%                  4.8%
Neonatal deaths                   0%                   2.4%
Foetal  malformation due to 
warfarin                    0%                      0%
These two studies are comparable in most variables.
SUMMARY
In this study of 129 pregnant women with RHD :
• The incidence  of  heart  disease  was 0.96% for  all  deliveries  during our  study 
period.
• The incidence of RHD was 71.6%
• 65.1% of women gave a h\o rheumatic fever
• 45(34.9%)  patients  had  undergone  surgical  correction  and  84(65.1%)  did  not 
undergo surgical correction.
• The  most  common  surgical  procedure  done  was  closed  mitral 
commisurotomy(80%).
• The most common valvular lesion was mitral stenosis(48.1%).
• 90.8% of patients belonged to class IV\V socioeconomic status.
• 86.6% of patients were between 21-28 years age.
• 95.3% had moderate to severe disease but only 18.6% were in NYHA class III/IV. 
Hence severity of disease did not correlate with NHYA class.
• 76.7% of  women had  vaginal  delivery.  LSCS was  done  for  obstetric  reasons 
alone.
• There were more preterm births and low birth weight babies in the not-operated 
group.
• There was no significant difference in the incidence of CCF between both groups.
• Women with mechanical valves had good maternal and fetal outcomes.
• Only 40.2% of women adopted some form of contraception.
  
 
CONCLUSION
According to this study, pregnant women with mitral stenosis still are at relatively 
high risk of experiencing maternal complications. The results  shown are consistent with 
those reported by other studies. 
The association of the pre pregnancy functional class with the risk of maternal 
events  raises attention to the possibility of  reducing these complications in pregnant 
women with mitral stenosis by means of early interventions aimed at improving their 
functional class. 
The mitral valve area was also strongly significantly associated with the risk of 
maternal events. If the mitral valve area was the only determining risk factor for events 
in  these  patients,  the  correction  of  high-degree  stenosis  should  correspond  to  a 
pronounced reduction of the occurrence of maternal complications during pregnancy and 
puerperium. 
Based on this assumption and with the purpose of reducing the gestational risks, 
interventional treatment (balloon mitral valvuloplasty or surgery) prior to conception has 
been recommended to patients with severe mitral stenosis who wish to get pregnant. 
However, like in the present study, usually women with mitral stenosis are referred for 
cardiological follow-up only after the beginning of pregnancy.   
Taking these facts  and the low incidence of  complications observed when the 
balloon mitral valvuloplasty is done during pregnancy this procedure should be seriously 
considered  for  all  types  of  valve  area,  independently  of  their  functional  class, 
particularly  if  we  take  into  account  that  acute  lung  edema  can  be  the  first  clinical 
manifestation of mitral stenosis during pregnancy .
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PROFORMA
Name:                                   IP.NO:                     LMP:                 DOA:
Age:                                      Unit:                        EDD:                  DOD:
                                                                              GPLA:
                                                                             Booking:
                                                                             Immunization:
I     Past H/O Rheumatic fever :
II    Gestional age at presentation:
      Associated pregnancy complications:
      Type of valvular lesion:
       NYHA:
       Associated Factors:  obesity/anemia/ fever
III    Past obstetric outcome:
       What and when:
IV    Surgical correction done:
V      H/O complications during antenatal period :    
VI    Purpose of admission:
VII    Labour stages:
                 Ist stage:    Posture:
                                     Analgesia:
                                     Duration:
                IInd stage:   Duration:
                                     Mode of delivery:
               IIIrd stage:    Complications:
VIII   Cesarean : Elective/ Emergency
                            Indication:
                            Type of anesthesia:
                             Complications:
                             Management
IX     Fetal outcome: Sex:
                                  Birth weight:
                                  Apgar: 
                                  Preterm/ term:
                                  Admission in NICU:
                                  Complications:
X    Contraception: Method adopted: 
                                Sterilization:    Type:           
                                                         Anesthesia :
                                                         Time of surgery
ABBREVIATIONS
MS :      Mitral Stenosis
MR :      Mitral Regurgitation
AR :       Aortic Regurgitation
AS :      Aortic Stenosis
TR :      Tricuspid Regurgitation
CMC :     Closed Mitral Commisurotomy.
BMV :     Balloon Mitral Valvuloplasty.
MVR :     Mitral Valve Replacement.
OMV :    Open Mitral Valvotomy.
MOD :    Moderate
SEV :    Severe
GPLA :    Gravida, Para, Live, Abortion.
B.WT :    Birth Weight
SA :    Spontaneous Abortions
COMP :   Complications
ST :    Sterilization
PROC :     Procedure
SB :    Still Born
HYB :    Hyperbilirubinemia
FEV :    Fever
IUD :    Intrauterine Death
CPD :    Cephalo Pelvic Disproportion
FD :    Fetal Distress
PULM EDEMA :    Pulmonary Edema
PROM :    Premature Rupture of Membranes
CCF :     Congestive Cardiac Failure
AF :      Atrial Fibrillation
EMBO :     Embolism
MVO :     Mitral Valve Orifice
MVA :     Mitral Valve Regurgitant Area
AVO :    Aortic Valve Orifice.
PHT :    Pulmonary Hypertension
RDS :    Respiratory Distress Syndrome
SEP :    Sepsis
TAT :    Trans Abdominal Tubectomy.
